Eli Lilly and Company (NYSE:LLY) Stock Price Up 0.7%

Eli Lilly and Company (NYSE:LLYGet Free Report) was up 0.7% on Wednesday . The company traded as high as $894.87 and last traded at $891.46. Approximately 2,437,038 shares changed hands during mid-day trading, a decline of 3% from the average daily volume of 2,510,363 shares. The stock had previously closed at $885.01.

Wall Street Analyst Weigh In

LLY has been the subject of several research reports. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. BMO Capital Markets boosted their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday. Finally, Truist Financial boosted their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $787.53.

Get Our Latest Stock Analysis on Eli Lilly and Company

Eli Lilly and Company Stock Up 0.7 %

The company has a market capitalization of $847.25 billion, a PE ratio of 131.29, a price-to-earnings-growth ratio of 1.93 and a beta of 0.36. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm has a 50-day moving average of $790.79 and a two-hundred day moving average of $723.56.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.62 earnings per share. Equities research analysts predict that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.58%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the transaction, the insider now directly owns 97,583,810 shares in the company, valued at $86,450,473,117.10. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the transaction, the insider now directly owns 97,583,810 shares in the company, valued at $86,450,473,117.10. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders sold a total of 762,804 shares of company stock worth $648,109,138 over the last ninety days. Company insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LLY. TruNorth Capital Management LLC purchased a new stake in Eli Lilly and Company during the 1st quarter worth about $265,000. NBW Capital LLC lifted its holdings in Eli Lilly and Company by 13.3% during the 1st quarter. NBW Capital LLC now owns 876 shares of the company’s stock worth $681,000 after buying an additional 103 shares during the last quarter. Keynote Financial Services LLC purchased a new stake in Eli Lilly and Company during the 1st quarter worth about $1,564,000. IMS Capital Management purchased a new stake in Eli Lilly and Company during the 1st quarter worth about $217,000. Finally, Jackson Wealth Management LLC lifted its holdings in Eli Lilly and Company by 2.6% during the 1st quarter. Jackson Wealth Management LLC now owns 6,495 shares of the company’s stock worth $5,053,000 after buying an additional 164 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.